Development of reliable, easy-to-use, rapid diagnostic tests (RDTs) to detect glucose-6-phosphate dehydrogenase (G6PD) deficiency at point of care is essential to deploying primaquine therapies as part of malaria elimination strategies. We assessed a kit under research and development called CareStart G6PD deficiency screening test (Access Bio, New Jersey, USA) by comparing its performance to q...

BACKGROUND beta-thalassemia is the most common inherited single gene disorder worldwide, and glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzyme deficiency. The goal of this study was to compare the frequency of beta-thalassemia trait and G6PD among the Moslem and Jewish populations in Shiraz, southern Iran. METHODS We examined 201 Moslems and 187 Jewish subjec...

PURPOSE To investigate the in vitro effects of gentamicin sulfate, vancomycin hydrochloride, sodium cefazolin and ceftriaxone on glucose 6-phosphate dehydrogenase enzyme (G6PD) purified from sheep lenses. METHODS G6PD was purified from sheep lenses with a yield of 66.8% and a specific activity of 7.8 U/mg proteins, and 10,400-fold using ammonium sulfate fractionation and 2,5-ADP Sepharose 4B ...

Historically, G6PD deficiency was reported for the first time in individuals who received doses of primaquine, primary drug to be addressed study, treat malaria, and triggered a symptomatic response with jaundice hematological field erythroenzymopathies. In this sense, through an integrative review, present research aimed discuss importance pharmaceutical care its relationship treatment patient...

The primary recognized health risk from common deficiencies in glucose-6-phosphate dehydrogenase (G6PD), a cytoprotective enzyme for oxidative stress, is red blood cell hemolysis. Here we show that litters from untreated pregnant mutant mice with a hereditary G6PD deficiency had increased prenatal (fetal resorptions) and postnatal death. When treated with the anticonvulsant drug phenytoin, a hu...

Glucose 6-phosphate dehydrogenase deficiency in an elite long-distance runner Glucose 6-phosphate dehydrogenase (G6PD) deficiency is the world's most common enzymopathy 1 and caused by mutations in the X-chromosomal G6PD gene. The enzyme catalyzes the first reaction of the hexose monophosphate shunt, which results in 2 main products: pentose phosphate sugars and the reduced form of nicotinamide...

BACKGROUND Although G6PD deficiency is the most common genetically determined blood disorder among Iraqis, its molecular basis has only recently been studied among the Kurds in North Iraq, while studies focusing on Arabs in other parts of Iraq are still absent. METHODS A total of 1810 apparently healthy adult male blood donors were randomly recruited from the national blood transfusion center...

BACKGROUND The use of cord blood in the neonatal screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency is being done with increasing frequency but has yet to be adequately evaluated against the use of peripheral blood sample which is usually employed for confirmation. We sought to determine the incidence and gender distribution of G6PD deficiency, and compare the results of cord aga...

Glucose-6-phosphate dehydrogenase (G6PD) represents a common human enzyme defect, particularly prevalent in the Mediterranean, African e Asian area, where malaria was or is still endemic. Recently, we identified G6PD deficiency as a risk factor for developing invasive fungal disease (IFD) and particularly Candida Sepsis in patients undergoing intensive chemotherapy for acute myeloid leukemia (A...

A variant of glucose-6-phosphate-dehyelectrophoretic mobility (B), and utilizadrogenase deficiency associated with tion of substrate analogues 2-deoxy-G6P chronic hereditary hemolytic anemia was and deamino-NADP were normal. The discovered in a 9-yr-old white male. The activity of G6PD in the leukocytes and erythrocytes contained 5% of normal platelets was 15% and 28% of normal enzyme activity,...